Advanced search
Publication Cover
Leukemia & Lymphoma Volume 57, 2016 - Issue 10
Submit an article Journal homepage
1,162
Views
23
CrossRef citations to date
0
Altmetric
Letters to the Editor

Impact of ruxolitinib treatment on the hemoglobin dynamics and the negative prognosis of anemia in patients with myelofibrosis

Haifa Kathrin Al-AliUniversity Hospital of Leipzig, Department of Hematology and Oncology, Leipzig, Germany; Correspondence[email protected]
,
Viktoriya StalbovskayaNovartis Pharma AG, Basel, Switzerland;
,
Prashanth GopalakrishnaNovartis Pharma AG, Basel, Switzerland;
,
Julian Perez-RoncoNovartis Pharma AG, Basel, Switzerland;
&
Lynda FoltzSt. Paul’s Hospital, University of British Columbia, Vancouver, Canada
Pages 2464-2467 | Received 29 Dec 2015, Accepted 19 Jan 2016, Published online: 25 Feb 2016

References

  • Cervantes F, Vannucchi AM, Kiladjian JJ, et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood. 2013;122:4047–4053.
  • Verstovsek S, Mesa RA, Gotlib J, et al. Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I. Haematologica. 2015;100:479–488.
  • Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366:787–798.
  • Sarr C, Urva S, Nedelman J, et al. Mathematical modeling of patient-level hemoglobin delineates ruxolitinib’s complex mechanism of action and quantifies anemia risk. Blood. 2014;124(Suppl). Abstract no. 3228.
  • Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the international working group for myelofibrosis research and treatment. Blood. 2009;113:2895–2901.
  • Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (international working group for myeloproliferative neoplasms research and treatment). Blood. 2010;115:1703–1708.
  • Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366:799–807.
  • Vannucchi AM, Kantarjian HM, Kiladjian JJ, et al. A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis. Haematologica. 2015;100:1139–1145.
  • Breccia M, Molica M, Colafigli G, et al. Improvement of bone marrow fibrosis with ruxolitinib: will this finding change our perception of the drug? Expert Rev Hematol. 2015;8:387–389.
  • Kvasnicka HM, Thiele J, Bueso-Ramos C, et al. Ruxolitinib induced modulation of bone marrow microenvironment in patients with myelofibrosis is associated with inflammatory cytokine levels. Blood. 2014;124(Suppl). Abstract no. 3182.
  • Mesa RA, Cortes J. Optimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing. J Hematol Oncol. 2013;6:79.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.